+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
16 Sep 2017

What is the difference between biosimilar and interchangeable biological products?

There are two new types of biological products- biosimilar and interchangeable.

  • Biosimilars are a type of biological product that are licensed (approved) by FDA because they are highly similar to an already FDA-approved biological product, known as the biological reference product (reference product), and have been shown to have no clinically meaningful differences from the reference product.
  • An interchangeable biological product, in addition to meeting the biosimilarity standard, is expected to produce the same clinical result as the reference product in any given patient.

The FDA will only approve a biosimilar product if it has the same mechanism of action, route of administration, dosage form, and strength as the reference product. Additionally, a biosimilar can only be approved for the indications and conditions of use that have been previously approved for the reference product.

Leave a Reply

Biotech & Biosimilar Regulatory Affairs and Strategic Management

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

1 Month Certification Program